Amyris Inc (NASDAQ:AMRS) was the recipient of some unusual options trading on Monday. Traders bought 966 put options on the stock. This represents an increase of 1,223% compared to the typical daily volume of 73 put options.
In related news, insider John Melo sold 10,776 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total value of $50,431.68. Following the sale, the insider now directly owns 83,172 shares in the company, valued at approximately $389,244.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 11.30% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tanaka Capital Management Inc. boosted its stake in shares of Amyris by 72.0% during the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after acquiring an additional 221,295 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Amyris during the 4th quarter worth $451,000. KBC Group NV boosted its stake in shares of Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 41,834 shares in the last quarter. Creative Planning bought a new stake in shares of Amyris during the 4th quarter worth $188,000. Finally, Compagnie Lombard Odier SCmA boosted its stake in shares of Amyris by 60.0% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after acquiring an additional 39,000 shares in the last quarter. 22.27% of the stock is owned by institutional investors and hedge funds.
AMRS stock opened at $6.76 on Wednesday. Amyris has a 1 year low of $1.86 and a 1 year high of $10.65. The stock has a market capitalization of $275.42, a price-to-earnings ratio of -1.82 and a beta of 0.38. The company has a debt-to-equity ratio of -0.78, a quick ratio of 0.82 and a current ratio of 0.92.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.24). The firm had revenue of $80.59 million during the quarter, compared to the consensus estimate of $68.14 million. During the same quarter in the previous year, the business posted ($0.09) EPS. The business’s revenue for the quarter was up 262.4% compared to the same quarter last year. sell-side analysts predict that Amyris will post -1.01 earnings per share for the current year.
Several equities analysts have recently issued reports on AMRS shares. Zacks Investment Research upgraded Amyris from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. HC Wainwright set a $15.00 price target on Amyris and gave the company a “buy” rating in a research report on Wednesday, November 29th. ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, February 23rd. B. Riley started coverage on Amyris in a research report on Thursday, January 25th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Cowen reiterated a “hold” rating and set a $4.00 price target on shares of Amyris in a research report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $8.19.
ILLEGAL ACTIVITY NOTICE: “Investors Purchase Large Volume of Amyris Put Options (AMRS)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/03/21/investors-purchase-large-volume-of-amyris-put-options-amrs.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.